Navigation Links
Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes

SAN FRANCISCO, Calif., March 26, 2007 /PRNewswire/ -- DiObex, Inc., a privately- held biopharmaceutical company focused on the development of therapeutics to treat metabolic diseases, today announced positive phase 2a results for DIO- 902, a novel Cortisol Synthesis Inhibitor.

In a recently completed multi-center, randomized, placebo-controlled trial, patients with type 2 diabetes were treated for two weeks to evaluate the safety, pharmacokinetics and activity of three dose levels of DIO-902. After two weeks of treatment, patients at all dose levels of DIO-902 showed significant reductions in total and LDL-cholesterol as well as trends toward an improvement in glycemic control as measured by HbA1c, fructosamine and fasting blood glucose. Mean levels of C-reactive protein, an inflammatory marker, were also significantly reduced. In contrast, metabolic control in patients in the placebo group remained stable or deteriorated slightly. These data lend support to the concept that abnormalities in cortisol activity may play an important role in the causation of type 2 diabetes and metabolic syndrome, a cluster of co-morbidities commonly associated with type 2 diabetes and insulin resistance. In the growing number of patients with type 2 diabetes and metabolic syndrome, co-morbidities such as hypertension and abnormal lipoprotein levels dramatically increase the risk of cardiovascular disease.

DIO-902 is one of two enantiomers contained within racemic ketoconazole, a marketed drug. Results of a separate drug-interaction study, conducted in normal healthy volunteers, in which Lipitor(R) (atorvastatin) was co- administered with DIO-902, support the co-administration of DIO-902 with the most commonly used doses of atorvastatin. This study also provided clinical evidence of a significant differential effect of DIO-902 and racemic ketoconazole on the metabolism of atorvastatin, thereby reducing the potential
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015  Delays in ... projects can slow down the decision-making process, resulting ... therefore, absolutely critical for biopharmaceutical companies to develop ... approval process for quicker and more meaningful insights. ... Best Practices, LLC, nearly three-quarters of benchmarked study ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ... Report on China,s Bevacizumab Market ,2010-2019" report to ... trade name of Avastin, bevacizumab injection is the first ... was approved by CFDA to treat metastatic colorectal cancer. ... all come from Roche and its subsidiary Genectech. ...
(Date:8/28/2015)... , Aug. 28, 2015 Patterson Medical, ... (Nasdaq: PDCO ), is now an independent ... acquisition of Patterson Medical by Madison Dearborn Partners ... its name for a transition period before rebranding ... and sports medicine products.  With the focused resources ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Bevacizumab Market 2015-2019 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ... the expansion of global cosmeceutical and skin care brands. Mr. Fernandez comes ... last 25 years working in operations, purchasing and management for some of the ...
(Date:8/29/2015)... ... August 30, 2015 , ... ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The ... simple digital handwritten signature. , Clinical trial sites can now use ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President ... to increase acceptance of the chiropractic field in the military. All too often VA ... Although Chiropractic was made available to the VA program over a decade ago, the ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring ... area with stretching, soft tissue manipulation. Platelet rich plasma injections also have ... research to improve treatment outcomes. This localized treatment seems to address the ...
(Date:8/28/2015)... Vegas, Nevada (PRWEB) , ... August 28, 2015 , ... ... announcing its decision to make the purchase of CPAP equipment more affordable by offering ... offer includes all types of CPAP products and orders of any size. My Cpap ...
Breaking Medicine News(10 mins):Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2
... April 9 Healthcare,workers at Tri-City Medical Center ... State Mediation & Conciliation Service,confirmed that caregivers strongly ... union authorization cards., TCMC caregivers become members ... thousands of other healthcare workers who have achieved ...
... PARK RIDGE, Ill., April 9 A study published ... Clinical Nutrition(i) suggests,an association between high egg consumption and ... not provide an explanation.,The researchers, Djousse and Gaziano, analyzed ... physicians over a 20 year period., The fact ...
... protein it expresses may cause some cases of the disease ... change in one gene, called CHI3L1, can increase a person,s ... causes the gene to release high levels of a protein ... been associated with an increased risk of asthma in past ...
... YORK, April 9 Duane Reade Holdings, Inc. today,announced ... has resigned from the Company to assume a senior ... resignation,will be effective on April 17, 2008., The ... Marketing Officer,position and will move swiftly to identify another ...
... stopped. But it can be predicted, and new research from ... lead healthier lives as a result. , Researchers have developed ... bodys bones. It reveals that the speed of physical aging ... (OSS), this new marker can be used by doctors ...
... N.J., April 9 Defined Health has,announced ... its 8th annual Therapeutic,Insight conference. Therapeutic Insight ... - 30, 2008, at The Westin New ... and key opinion leaders will discuss relevant,pharma/biotech ...
Cached Medicine News:Health News:North County Caregivers Join United Healthcare Workers 2Health News:Statement by the American Egg Board and Egg Nutrition Center on AJCN Study on Egg Consumption 2Health News:Statement by the American Egg Board and Egg Nutrition Center on AJCN Study on Egg Consumption 3Health News:Researchers Find Gene Mutation That Increases Asthma Risk 2Health News:Researchers Find Gene Mutation That Increases Asthma Risk 3Health News:Duane Reade Holdings, Inc. Announces Resignation of Chief Marketing Officer 2Health News:How fast you'll age is written in the bones, TAU research finds 2Health News:Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008 2Health News:Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008 3
Colloidal Gold Conjugated, Rabbit anti-goat IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Protein A - 50 OD...
Colloidal Gold Conjugated, Protein G - 50 OD...
Polyester ribbon impregnated with conjugated Protein G - .25 OD per sq. cm....
Medicine Products: